Trial Profile
Efficacy and Safety of Intensive Insulin Therapy With Insulin Glulisine in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary) ; Insulin glulisine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms CHANGING
- Sponsors Sanofi
- 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Mar 2012 Planned number of patients changed from 284 to 200 as reported by ClinicalTrials.gov.
- 26 Mar 2012 Planned End Date changed from 1 Aug 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.